Abdominal Pain, Altered Mental Status in a 60-year-old Woman

Poll

VIDEO: Patient reports progressive weakness x1 month. Acute abdominal pain/emesis began earlier in the day. What's in your differential dx?


 

Patient reports feeling weak x1 month; husband describes low-grade fevers. Acute abdominal pain, emesis began this morning; no diarrhea. PMH: recent dx of factor V Leiden; no medications. Vitals: Temp: 97.4oF;HR: 76 bpm, RR: 16, BP: 124/63. Review video of ED interview.

 

What's your diagnosis?

A. Endocarditis with likely septic emboli to brain
B. Other infection (meningitis, UTI, pneumonia)
C. Stroke
D. Sinus venous thrombosis
E. Dehydration
F. Electrolyte abnormality (hyponatremia, hypokalemia)
Recent Videos
Primary Care is the Answer to the Migraine Care Gap, Says Headache Specialist
Related Content
Investigational Nonopioid Beats Placebo in Phase 3 Trial: Daily Dose / image credit: ©New Africa/AdobeStock

Investigational Nonopioid Beats Placebo in Phase 3 Trial: Daily Dose

Sydney Jennings
February 12th 2025
Article

Your daily dose of the clinical news you may have missed.

Obesity & Pain Management: A Primary Viewpoints Podcast

Obesity & Pain Management: A Primary Viewpoints Podcast

Sydney Jennings
April 27th 2023
Podcast

In our latest episode, an obesity medicine physician explains the importance of a comprehensive plan to manage chronic pain in patients with obesity.

FDA Approves Nonopioid Journavx for Acute Pain: Daily Dose / image credit: ©New Africa/AdobeStock

FDA Approves Nonopioid Journavx for Acute Pain: Daily Dose

Sydney Jennings
February 10th 2025
Article

Your daily dose of the clinical news you may have missed.

Primary Viewpoints Episode 19: Mobile Health Technology for Chronic Pain Management

Primary Viewpoints Episode 19: Mobile Health Technology for Chronic Pain Management

Sydney Jennings
September 29th 2022
Podcast

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Lynn Webster, MD, past president of the American Academy of Pain Medicine.

Tris Pharma's Cebranopadol Shows Low Potential for Misuse in Intranasal Human Abuse Potential Study / image credit ©Dx Photo/stock.adobe.com

Tris Pharma's Cebranopadol Shows Low Potential for Misuse in Intranasal Human Abuse Potential Study

Grace Halsey
January 29th 2025
Article

The novel dual NMR agonist was scored significantly less "likable" when crushed and taken intranasally compared with oxycodone, the company reported.

Cebranopadol Achieves Positive Phase 3 Results for Treatment of Moderate-to-Severe Acute Pain

Cebranopadol Achieves Positive Phase 3 Results for Treatment of Moderate-to-Severe Acute Pain

Patient Care Editorial Staff
January 22nd 2025
Article

Cebranopadol, an investigational oral dual-NMR agonist, satisfied the primary endpoint of statistically significant reduction in pain intensity compared to placebo following abdominoplasty surgery.

© 2025 MJH Life Sciences

All rights reserved.